Supplements are the hardest category on Meta right now.
Every claim is a policy minefield.
Meta pulls ads for words your brand team signed off on. You lose 6 ad sets a month to rejections that nobody can explain. Your CPMs bake in the policy risk.
First-order CAC says nothing about the business.
A $55 CAC with 18% subscribe rate is a slow death. A $80 CAC with 48% subscribe rate is a market-leading business. Most dashboards don't even show that comparison.
Ingredient stories get ignored for 'benefit' hooks.
'Stop feeling bloated' beats 'with L-glutamine' on CTR. But L-glutamine as the hero beats benefit-forward on subscription rate. Creative portfolios need both — most brands only test one.
How we run supplement brands.
Claims + mechanism map
Audit every claim against FTC + Meta policy. Map hero ingredients to mechanism-of-action. Identify the 4 angles most likely to convert subscribers vs. one-timers.
Creative concept bank
Build 20 concepts across founder, doctor, testimonial, ingredient, and demo formats. Every claim has a pre-approved substantiation reference.
Subscription-first CAC model
Blended CAC target set by subscribe rate × gross margin × expected months. Not cost-per-first-order. This alone changes which audiences you scale.
Portfolio + Applovin
Meta + TikTok + YouTube + Applovin as one portfolio. Applovin consistently under-valued for supplements — our top accounts get 20–30% of spend there.
Brands we've moved numbers for.
Took a single-SKU collagen brand from $600k to $1.2M/mo while increasing subscription rate from 31% to 49%. Applovin became the #2 channel by month 6.
Ran creative across mechanism-of-action angles the previous agency ignored. Subscribe rate on Applovin matched Meta within 90 days.
Nootropic category is brutal on Meta. Built a creator-heavy portfolio with doctor-led explainer formats. Subscription rate jumped from 27% to 43%.
Creative we've shipped for Supplements brands.
Static, story and video units from accounts we've run. Each one tested against a kill rule, not a subjective review.









